137 related articles for article (PubMed ID: 9457895)
1. The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro.
Larsen RH; Akabani G; Welsh P; Zalutsky MR
Radiat Res; 1998 Feb; 149(2):155-62. PubMed ID: 9457895
[TBL] [Abstract][Full Text] [Related]
2. Radiation doses to non-Hodgkin's lymphoma cells and normal bone marrow exposed in vitro. Comparison of an alpha-emitting radioimmunoconjugate and external gamma-irradiation.
Aurlien E; Kvinnsland Y; Larsen RH; Bruland ØS
Int J Radiat Biol; 2002 Feb; 78(2):133-42. PubMed ID: 11779363
[TBL] [Abstract][Full Text] [Related]
3. The survival of monolayers of cells growing in clusters irradiated by 211At appended to the cell surfaces.
Charlton DE
Radiat Res; 1999 Jun; 151(6):750-3. PubMed ID: 10360796
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model.
Lee YS; Bullard DE; Zalutsky MR; Coleman RE; Wikstrand CJ; Friedman HS; Colapinto EV; Bigner DD
Cancer Res; 1988 Feb; 48(3):559-66. PubMed ID: 2446747
[TBL] [Abstract][Full Text] [Related]
5. In vitro cytotoxicity of (211)at-astatide and (131)I-iodide to glioma tumor cells expressing the sodium/iodide symporter.
Carlin S; Akabani G; Zalutsky MR
J Nucl Med; 2003 Nov; 44(11):1827-38. PubMed ID: 14602867
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of human osteosarcoma cells in vitro by 211At-TP-3 monoclonal antibody: comparison with astatine-211-labeled bovine serum albumin, free astatine-211 and external-beam X rays.
Larsen RH; Bruland OS; Hoff P; Alstad J; Lindmo T; Rofstad EK
Radiat Res; 1994 Aug; 139(2):178-84. PubMed ID: 8052693
[TBL] [Abstract][Full Text] [Related]
7. Compartmental distribution of tumor-specific monoclonal antibodies in human melanoma xenografts.
Lin K; Nagy JA; Xu H; Shockley TR; Yarmush ML; Dvorak HF
Cancer Res; 1994 Apr; 54(8):2269-77. PubMed ID: 8174137
[TBL] [Abstract][Full Text] [Related]
8. In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction.
Akabani G; Carlin S; Welsh P; Zalutsky MR
Nucl Med Biol; 2006 Apr; 33(3):333-47. PubMed ID: 16631082
[TBL] [Abstract][Full Text] [Related]
9. Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate.
Zalutsky MR; McLendon RE; Garg PK; Archer GE; Schuster JM; Bigner DD
Cancer Res; 1994 Sep; 54(17):4719-25. PubMed ID: 8062270
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity of alpha-particle-emitting 5-[211At]astato-2'-deoxyuridine in human cancer cells.
Larsen RH; Vaidyanathan G; Zalutsky MR
Int J Radiat Biol; 1997 Jul; 72(1):79-90. PubMed ID: 9246197
[TBL] [Abstract][Full Text] [Related]
11. Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2.
Elgqvist J; Andersson H; Bernhardt P; Bäck T; Claesson I; Hultborn R; Jensen H; Johansson BR; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1228-37. PubMed ID: 17145538
[TBL] [Abstract][Full Text] [Related]
12. Microdosimetric analysis of alpha-particle-emitting targeted radiotherapeutics using histological images.
Akabani G; Kennel SJ; Zalutsky MR
J Nucl Med; 2003 May; 44(5):792-805. PubMed ID: 12732682
[TBL] [Abstract][Full Text] [Related]
13. High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use.
Zalutsky MR; Zhao XG; Alston KL; Bigner D
J Nucl Med; 2001 Oct; 42(10):1508-15. PubMed ID: 11585865
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
Elgqvist J; Andersson H; Bäck T; Hultborn R; Jensen H; Karlsson B; Lindegren S; Palm S; Warnhammar E; Jacobsson L
J Nucl Med; 2005 Nov; 46(11):1907-15. PubMed ID: 16269606
[TBL] [Abstract][Full Text] [Related]
15. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.
Bäck T; Andersson H; Divgi CR; Hultborn R; Jensen H; Lindegren S; Palm S; Jacobsson L
J Nucl Med; 2005 Dec; 46(12):2061-7. PubMed ID: 16330571
[TBL] [Abstract][Full Text] [Related]
16. In vitro effects of free 211At,211At-albumin and 211At-monoclonal antibody compared to external photon irradiation on two human cancer cell lines.
Palm S; Andersson H; Bäck T; Claesson I; Delle U; Hultborn R; Jacobsson L; Köpf I; Lindegren S
Anticancer Res; 2000; 20(2A):1005-12. PubMed ID: 10810388
[TBL] [Abstract][Full Text] [Related]
17. 5-[211 At]astato-2'-deoxyuridine, an alpha particle-emitting endoradiotherapeutic agent undergoing DNA incorporation.
Vaidyanathan G; Larsen RH; Zalutsky MR
Cancer Res; 1996 Mar; 56(6):1204-9. PubMed ID: 8640798
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxicity of alpha-particle-emitting astatine-211-labelled antibody in tumour spheroids: no effect of hyperthermia.
Hauck ML; Larsen RH; Welsh PC; Zalutsky MR
Br J Cancer; 1998 Mar; 77(5):753-9. PubMed ID: 9514054
[TBL] [Abstract][Full Text] [Related]
19. Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice.
Elgqvist J; Bernhardt P; Hultborn R; Jensen H; Karlsson B; Lindegren S; Warnhammar E; Jacobsson L
J Nucl Med; 2005 Mar; 46(3):464-71. PubMed ID: 15750160
[TBL] [Abstract][Full Text] [Related]
20. Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis.
McLendon RE; Archer GE; Larsen RH; Akabani G; Bigner DD; Zalutsky MR
Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):491-9. PubMed ID: 10487576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
